A Psychedelic Biotech CEO Writes $1.35M, and Two Others Followed
Michael Halstead runs Cybin, a clinical-stage drug developer working on psilocybin and DMT-based therapies for depression and anxiety, with a lead candidate already in Phase 3. His $1,347,050 buy is his first ever on this ticker, and two other insiders have stepped in over the past 30 days, so this isn't one guy acting alone. The technicals are cooperating too. Price just crossed back above the 8-day at $13.66, the 20-day sits under it at $12.68, and all three trend timeframes read Buy while healthcare holds firm against a risk-off tape. A trader who agrees with Halstead could sell a put spread beneath his $13.47 entry to get paid while waiting for a cheaper look, though remember this is a clinical-stage name where trial data can move the stock hard in either direction.
The Filing
| Ticker | HELP |
| Company | CYBIN INC. |
| Insider | Michael Halstead, Chief Executive Officer |
| Buy amount | $1.3M |
| Filing date | September 21, 2026 |
| Conviction | Interesting · 61/100 |
| Setup type | Trend Confirmation |
Ultimate members received this analysis in real time.